Indacaterol (Arcapta)

Indications


Pharmacology

  • Ultra Long-Acting β2-Adrenergic Receptor Agonist (see β2-Adrenergic Receptor Agonists, [[β2-Adrenergic Receptor Agonists]]): 24 hr sustained bronchodilation
    • Improved FEV1: fast onset of action (FEV1 improvement is seen as early as 5 min after dose)
    • Decreased rescue medication use
    • Improved health-related quality of life (by St. George’s respiratory questionnaire)

Administration

  • INH: 75 ug qday (dry powder capsule, used in neohaler device)

Adverse Effects

Pulmonary Adverse Effects

  • Cough (see Cough, [[Cough]])
  • Nasopharyngitis (see Pharyngitis, [[Pharyngitis]])
  • LABA FDA Black-Box Warning in Asthma: all LABA’s carry this warning, although indacaterol is not indicated for asthma

Gastrointestinal Adverse Effects

Neurological Adverse Effects

Other Adverse Effects

  • xxx

References

  • xxx